Abbott Laboratories ABT recently announced the acquisition of Walk Vascular, LLC -- a commercial-stage medical device company with a minimally-invasive mechanical aspiration thrombectomy system. The website you have requested also may not be optimized for your specific screen size. Trial on its small implantable pulmonary pressure sensor, CardioMEMS HF system a commercial-stage Medical device company Walk Vascular well. Abbott Laboratories - Wikipedia Abbott. TCS New York City Marathon Talent Acquisition Specialist - Nutrition - Abbott - LinkedIn CLOSE. Full-year 2021 worldwide sales increased 24.5 percent on a reported basis and 22.9 percent on an organic basis. Abbott Laboratories' largest acquisition to date was in 2016, when it acquired St. Jude Medical for $25.0B. The acquisition will expand Abbotts Peripheral Vascular offerings, boosting the companys vascular businesses. Per Abbotts management, Vascular's technology offers physicians with tools to efficiently remove dangerous clots from blood vessels. Abbott Reports Strong Fourth-Quarter 2021 Results; Issues 2022 Forecast, - Fourth-quarter sales growth of 7.2 percent; organic sales growth of 7.7 percent, - Global COVID-19 testing-related sales of $2.3 billion in the fourth quarter, - Excluding COVID-19 testing-related sales, fourth-quarter sales growth of 9.6 percent and organic sales growth of 10.3 percent, - Full-year 2021 sales growth of 24.5 percent; organic sales growth of 22.9 percent, - Full-year 2021 GAAP diluted EPS from continuing operations growth of 58.2 percent; adjusted diluted EPS growth of 42.7 percent, - R&D pipeline continues to deliver a steady cadence of new products, including several in large, fast-growing markets, For further information: Abbott Financial: Scott Leinenweber, 224-668-0791; Michael Comilla, 224-668-1872; Laura Dauer, 224-667-2299; Abbott Media: Scott Stoffel, 224-668-5201; Kate Dyer, 224-668-9965, Full-year 2021 GAAP diluted EPS from continuing operations was, Global COVID-19 testing-related sales were, Abbott issues full-year 2022 guidance for diluted EPS from continuing operations on a GAAP basis of at least, Full-year 2022 guidance includes an initial COVID-19 testing-related sales forecast of, Abbott's R&D pipeline continues to deliver a steady cadence of new products. It's been a full year since Abbott closed its $5.3 billion acquisition of Alere, a deal that almost didn't happen. Quick Access Toolbar Word 2019,